Home >> Research Area >>Natural Products>>Diterpenoids>> 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one

19-Nor-4-hydroxyabieta-8,11,13-trien-7-one

CAS# 57906-31-7

19-Nor-4-hydroxyabieta-8,11,13-trien-7-one

2D Structure

Catalog No. BCN1411----Order now to get a substantial discount!

Product Name & Size Price Stock
19-Nor-4-hydroxyabieta-8,11,13-trien-7-one: 5mg Please Inquire In Stock
19-Nor-4-hydroxyabieta-8,11,13-trien-7-one: 10mg Please Inquire In Stock
19-Nor-4-hydroxyabieta-8,11,13-trien-7-one: 20mg Please Inquire Please Inquire
19-Nor-4-hydroxyabieta-8,11,13-trien-7-one: 50mg Please Inquire Please Inquire
19-Nor-4-hydroxyabieta-8,11,13-trien-7-one: 100mg Please Inquire Please Inquire
19-Nor-4-hydroxyabieta-8,11,13-trien-7-one: 200mg Please Inquire Please Inquire
19-Nor-4-hydroxyabieta-8,11,13-trien-7-one: 500mg Please Inquire Please Inquire
19-Nor-4-hydroxyabieta-8,11,13-trien-7-one: 1000mg Please Inquire Please Inquire

Quality Control of 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one

3D structure

Package In Stock

19-Nor-4-hydroxyabieta-8,11,13-trien-7-one

Number of papers citing our products

Chemical Properties of 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one

Cas No. 57906-31-7 SDF Download SDF
PubChem ID 91884799 Appearance Powder
Formula C19H26O2 M.Wt 286.4
Type of Compound Diterpenoids Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name (1S,4aS,10aR)-1-hydroxy-1,4a-dimethyl-7-propan-2-yl-3,4,10,10a-tetrahydro-2H-phenanthren-9-one
SMILES CC(C)C1=CC2=C(C=C1)C3(CCCC(C3CC2=O)(C)O)C
Standard InChIKey PTQFIYQNKVSVGM-QRVBRYPASA-N
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one

The heart wood of Pinus yunnanensis

19-Nor-4-hydroxyabieta-8,11,13-trien-7-one Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

19-Nor-4-hydroxyabieta-8,11,13-trien-7-one Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.4916 mL 17.4581 mL 34.9162 mL 69.8324 mL 87.2905 mL
5 mM 0.6983 mL 3.4916 mL 6.9832 mL 13.9665 mL 17.4581 mL
10 mM 0.3492 mL 1.7458 mL 3.4916 mL 6.9832 mL 8.7291 mL
50 mM 0.0698 mL 0.3492 mL 0.6983 mL 1.3966 mL 1.7458 mL
100 mM 0.0349 mL 0.1746 mL 0.3492 mL 0.6983 mL 0.8729 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one

Insulin Resistance Predicts Cognitive Decline: An 11-Year Follow-up of a Nationally Representative Adult Population Sample.[Pubmed:28381479]

Diabetes Care. 2017 Jun;40(6):751-758.

OBJECTIVE: The aim of this study was to examine whether insulin resistance, assessed by HOMA of insulin resistance (HOMA-IR), is an independent predictor of cognitive decline. RESEARCH DESIGN AND METHODS: The roles of HOMA-IR, fasting insulin and glucose, HbA1c, and hs-CRP as predictors of cognitive performance and its change were evaluated in the Finnish nationwide, population-based Health 2000 Health Examination Survey and its 11-year follow-up, the Health 2011 study (n = 3,695, mean age at baseline 49.3 years, 55.5% women). Categorical verbal fluency, word-list learning, and word-list delayed recall were used as measures of cognitive function. Multivariate linear regression analysis was performed and adjusted for previously reported risk factors for cognitive decline. RESULTS: Higher baseline HOMA-IR and fasting insulin levels were independent predictors of poorer verbal fluency performance (P = 0.0002 for both) and of a greater decline in verbal fluency during the follow-up time (P = 0.004 for both). Baseline HOMA-IR and insulin did not predict word-list learning or word-list delayed recall scores. There were no interactions between HOMA-IR and apolipoprotein E epsilon4 (APOEepsilon4) genotype, hs-CRP, or type 2 diabetes on the cognitive tests. Fasting glucose and hs-CRP levels at baseline were not associated with cognitive functioning. CONCLUSIONS: Our results show that higher serum fasting insulin and insulin resistance predict poorer verbal fluency and a steeper decline in verbal fluency during 11 years in a representative sample of an adult population. Prevention and treatment of insulin resistance might help reduce cognitive decline later in life.

GNG11 (G-protein subunit gamma 11) suppresses cell growth with induction of reactive oxygen species and abnormal nuclear morphology in human SUSM-1 cells.[Pubmed:28380310]

Biochem Cell Biol. 2017 Aug;95(4):517-523.

Enforced expression of GNG11, G-protein subunit gamma 11, induces cellular senescence in normal human diploid fibroblasts. We here examined the effect of the expression of GNG11 on the growth of immortalized human cell lines, and found that it suppressed the growth of SUSM-1 cells, but not of HeLa cells. We then compared these two cell lines to understand the molecular basis for the action of GNG11. We found that expression of GNG11 induced the generation of reactive oxygen species (ROS) and abnormal nuclear morphology in SUSM-1 cells but not in HeLa cells. Increased ROS generation by GNG11 would likely be caused by the down-regulation of the antioxidant enzymes in SUSM-1 cells. We also found that SUSM-1 cells, even under normal culture conditions, showed higher levels of ROS and higher incidence of abnormal nuclear morphology than HeLa cells, and that abnormal nuclear morphology was relevant to the increased ROS generation in SUSM-1 cells. Thus, SUSM-1 and HeLa cells showed differences in the regulation of ROS and nuclear morphology, which might account for their different responses to the expression of GNG11. Thus, SUSM-1 cells may provide a unique system to study the regulatory relationship between ROS generation, nuclear morphology, and G-protein signaling.

Access to percutaneous transluminal coronary angioplasty and 30-day mortality in patients with incident STEMI: Differentials by educational level and gender over 11 years.[Pubmed:28384181]

PLoS One. 2017 Apr 6;12(4):e0175038.

BACKGROUND: Socioeconomic status and gender are associated with access to cardiac procedures and mortality after AMI, also in countries with universal health care systems. Our objective was to evaluate the association and trends of educational level or gender and the following outcomes: 1) access to PTCA; 2) 30-day mortality. METHODS: We conducted an observational study based on 14,013 subjects aged 35-74 years, residing in Rome in 2001, and hospitalised for incident STEMI within 2012 in the Lazio region. We estimated adjusted ORs of educational level or gender and: 1) PTCA within 2 days after hospitalisation, 2) 30-day mortality. We evaluated time trends of outcomes, and time trends of educational or gender differentials estimating ORs stratified by time period (two time periods between 2001 and 2012). We performed a hierarchical analysis to account for clustering of hospitals. RESULTS: Access to PTCA among patients with incident STEMI increased during the study period, while 30-day mortality was stable. We observed educational differentials in PTCA procedure only in the first time period, and gender differentials in both periods. Patterns for 30-day mortality were less marked, with educational differentials emerging only in the second period, and gender differentials only in the first one, with patients with low educational level and females being disadvantaged. CONCLUSIONS: Educational differentials in the access to PTCA disappeared in Lazio region over time, coherently with scientific literature, while gender differentials seem to persist. It may be important to assess the role of female gender in patients with STEMI, both from a social and a clinical point of view.

Simultaneous quantification of 11 active constituents in Shexiang Baoxin Pill by ultraperformance convergence chromatography combined with tandem mass spectrometry.[Pubmed:28384605]

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 May 1;1052:135-141.

On account of the complexity of chemical constituents of Shexiang Baoxin Pill (SBP), a famous traditional Chinese medicine (TCM) formula, a novel and effective UPC(2)-MS/MS method was developed to simultaneously determine the content of 11 active compounds of SBP with outstanding separation ability. Eleven components in SBP, including 2 ginsenosides, 2 bile acids, 3 bufadienolides and 4 volatiles were detected by electrospray ionization tandem mass spectrometry in positive and negative ion modes with multiple reaction monitor (MRM). The analysis was performed at 30 degrees C using an Acquity UPC(2) Diol (3.0x50mm, 1.7mum) column with linear gradient elution (eluent A, CO2; eluent B, methanol containing 20mM ammonium acetate), back pressure of 2000 psi, flow rate of 1.2mL/min and the injection volume of 1.0muL. The method was extensively validated regarding the linearity (r>/=0.9974), precision (

Keywords:

19-Nor-4-hydroxyabieta-8,11,13-trien-7-one,57906-31-7,Natural Products, buy 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one , 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one supplier , purchase 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one , 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one cost , 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one manufacturer , order 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one , high purity 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: